Comments
Loading...

Surgery Partners Analyst Ratings

SGRYNASDAQ
Logo brought to you by Benzinga Data
$23.95
-0.17-0.70%
At close: -
$23.95
0.000.00%
After Hours: Mar 28, 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$51.00
Lowest Price Target1
$28.00
Consensus Price Target1
$39.92

Surgery Partners Analyst Ratings and Price Targets | NASDAQ:SGRY | Benzinga

Surgery Partners Inc has a consensus price target of $39.92 based on the ratings of 14 analysts. The high is $51 issued by Barclays on August 2, 2023. The low is $28 issued by JP Morgan on December 3, 2024. The 3 most-recent analyst ratings were released by RBC Capital, Macquarie, and JP Morgan on March 25, 2025, March 11, 2025, and December 3, 2024, respectively. With an average price target of $32 between RBC Capital, Macquarie, and JP Morgan, there's an implied 33.61% upside for Surgery Partners Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Oct 24
4
Nov 24
1
Dec 24
2
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

RBC Capital
Macquarie
JP Morgan
UBS
Cantor Fitzgerald

1calculated from analyst ratings

Analyst Ratings for Surgery Partners

Buy NowGet Alert
03/25/2025Buy Now46.14%RBC Capital
Ben Hendrix60%
$35 → $35ReiteratesOutperform → OutperformGet Alert
03/11/2025Buy Now37.79%Macquarie
Tao Qiu46%
$34 → $33MaintainsOutperformGet Alert
12/03/2024Buy Now16.91%JP Morgan
Lisa Gill59%
$38 → $28MaintainsNeutralGet Alert
11/20/2024Buy Now46.14%RBC Capital
Ben Hendrix60%
$49 → $35MaintainsOutperformGet Alert
11/19/2024Buy Now41.96%Macquarie
Tao Qiu46%
$34 → $34MaintainsOutperformGet Alert
11/13/2024Buy Now41.96%Macquarie
Tao Qiu46%
$35 → $34MaintainsOutperformGet Alert
11/04/2024Buy Now46.14%Macquarie
Tao Qiu46%
$35 → $35MaintainsOutperformGet Alert
10/14/2024Buy Now58.66%UBS
A.J. Rice68%
→ $38Initiates → BuyGet Alert
10/11/2024Buy NowKeybanc
Matthew Gillmor65%
Initiates → Sector WeightGet Alert
10/04/2024Buy Now79.54%Cantor Fitzgerald
Sarah James51%
$43 → $43ReiteratesOverweight → OverweightGet Alert
08/26/2024Buy Now108.77%Benchmark
Bill Sutherland62%
$50 → $50ReiteratesBuy → BuyGet Alert
08/20/2024Buy Now79.54%Cantor Fitzgerald
Sarah James51%
$43 → $43ReiteratesOverweight → OverweightGet Alert
08/19/2024Buy Now79.54%Cantor Fitzgerald
Sarah James51%
$43 → $43ReiteratesOverweight → OverweightGet Alert
08/07/2024Buy Now50.31%Citigroup
Jason Cassorla50%
$38 → $36MaintainsBuyGet Alert
08/07/2024Buy Now108.77%Benchmark
Bill Sutherland62%
$50 → $50ReiteratesBuy → BuyGet Alert
08/07/2024Buy Now104.59%RBC Capital
Ben Hendrix60%
$49 → $49ReiteratesOutperform → OutperformGet Alert
07/10/2024Buy Now79.54%Cantor Fitzgerald
Sarah James51%
$43 → $43ReiteratesOverweight → OverweightGet Alert
07/09/2024Buy Now79.54%Cantor Fitzgerald
Sarah James51%
$43 → $43ReiteratesOverweight → OverweightGet Alert
07/02/2024Buy Now79.54%Cantor Fitzgerald
Sarah James51%
$43 → $43ReiteratesOverweight → OverweightGet Alert
06/28/2024Buy Now29.44%Macquarie
Tao Qiu46%
→ $31Initiates → OutperformGet Alert
05/08/2024Buy Now58.66%Citigroup
Jason Cassorla50%
$42 → $38MaintainsBuyGet Alert
05/01/2024Buy Now108.77%Benchmark
Bill Sutherland62%
$50 → $50ReiteratesBuy → BuyGet Alert
04/10/2024Buy Now79.54%Cantor Fitzgerald
Sarah James51%
$43 → $43ReiteratesOverweight → OverweightGet Alert
03/06/2024Buy Now46.14%Barclays
Andrew Mok55%
→ $35Initiates → Equal-WeightGet Alert
03/05/2024Buy Now79.54%Cantor Fitzgerald
Sarah James51%
$43 → $43ReiteratesOverweight → OverweightGet Alert
02/29/2024Buy Now104.59%RBC Capital
Ben Hendrix60%
$49 → $49ReiteratesOutperform → OutperformGet Alert
02/27/2024Buy Now75.37%Citigroup
Jason Cassorla50%
$43 → $42MaintainsBuyGet Alert
02/27/2024Buy Now79.54%Cantor Fitzgerald
Sarah James51%
$43 → $43MaintainsOverweightGet Alert
11/14/2023Buy Now46.14%TD Cowen
Gary Taylor59%
$39 → $35UpgradeMarket Perform → OutperformGet Alert
10/12/2023Buy Now108.77%Benchmark
Bill Sutherland62%
→ $50ReiteratesBuy → BuyGet Alert
09/14/2023Buy Now79.54%Cantor Fitzgerald
Sarah James51%
→ $43ReiteratesOverweight → OverweightGet Alert
08/02/2023Buy Now108.77%Benchmark
Bill Sutherland62%
→ $50ReiteratesBuy → BuyGet Alert
08/02/2023Buy Now112.94%Barclays
Marc Solecitto64%
$56 → $51MaintainsOverweightGet Alert
07/31/2023Buy Now108.77%Benchmark
Bill Sutherland62%
→ $50ReiteratesBuy → BuyGet Alert
07/11/2023Buy Now108.77%Mizuho
Ann Hynes86%
$48 → $50MaintainsBuyGet Alert
06/02/2023Buy Now87.89%B of A Securities
Kevin Fischbeck67%
$42 → $45UpgradeNeutral → BuyGet Alert
05/12/2023Buy Now100.42%Mizuho
Ann Hynes86%
→ $48Initiates → BuyGet Alert
05/02/2023Buy Now96.24%RBC Capital
Ben Hendrix60%
→ $47Reiterates → OutperformGet Alert
05/02/2023Buy Now108.77%Benchmark
Bill Sutherland62%
→ $50Reiterates → BuyGet Alert
05/02/2023Buy Now96.24%Citigroup
Jason Cassorla50%
$40 → $47MaintainsBuyGet Alert
04/21/2023Buy Now79.54%Cantor Fitzgerald
Sarah James51%
→ $43Initiates → OverweightGet Alert
03/06/2023Buy Now96.24%Benchmark
Bill Sutherland62%
→ $47Reiterates → BuyGet Alert
03/02/2023Buy Now67.01%JP Morgan
Lisa Gill59%
$45 → $40MaintainsNeutralGet Alert
01/18/2023Buy Now133.82%Barclays
Marc Solecitto64%
$69 → $56MaintainsOverweightGet Alert
12/05/2022Buy Now96.24%Benchmark
Bill Sutherland62%
$60 → $47MaintainsBuyGet Alert
11/23/2022Buy Now100.42%RBC Capital
Ben Hendrix60%
$58 → $48MaintainsOutperformGet Alert
11/22/2022Buy Now67.01%SVB Leerink
Whit Mayo67%
$55 → $40MaintainsOutperformGet Alert
11/10/2022Buy Now142.17%RBC Capital
Ben Hendrix60%
$62 → $58MaintainsOutperformGet Alert
11/10/2022Buy Now129.65%SVB Leerink
Whit Mayo67%
$57 → $55MaintainsOutperformGet Alert
11/09/2022Buy Now58.66%Citigroup
Jason Cassorla50%
$49 → $38MaintainsBuyGet Alert
08/03/2022Buy Now158.87%RBC Capital
Ben Hendrix60%
$65 → $62MaintainsOutperformGet Alert
06/15/2022Buy Now50.31%B of A Securities
Kevin Fischbeck67%
→ $36DowngradeBuy → NeutralGet Alert
05/04/2022Buy Now167.22%Citigroup
Jason Cassorla50%
$61 → $64MaintainsBuyGet Alert

FAQ

Q

What is the target price for Surgery Partners (SGRY) stock?

A

The latest price target for Surgery Partners (NASDAQ:SGRY) was reported by RBC Capital on March 25, 2025. The analyst firm set a price target for $35.00 expecting SGRY to rise to within 12 months (a possible 46.14% upside). 23 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Surgery Partners (SGRY)?

A

The latest analyst rating for Surgery Partners (NASDAQ:SGRY) was provided by RBC Capital, and Surgery Partners reiterated their outperform rating.

Q

When was the last upgrade for Surgery Partners (SGRY)?

A

The last upgrade for Surgery Partners Inc happened on November 14, 2023 when TD Cowen raised their price target to $35. TD Cowen previously had a market perform for Surgery Partners Inc.

Q

When was the last downgrade for Surgery Partners (SGRY)?

A

The last downgrade for Surgery Partners Inc happened on June 15, 2022 when B of A Securities changed their price target from N/A to $36 for Surgery Partners Inc.

Q

When is the next analyst rating going to be posted or updated for Surgery Partners (SGRY)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Surgery Partners, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Surgery Partners was filed on March 25, 2025 so you should expect the next rating to be made available sometime around March 25, 2026.

Q

Is the Analyst Rating Surgery Partners (SGRY) correct?

A

While ratings are subjective and will change, the latest Surgery Partners (SGRY) rating was a reiterated with a price target of $35.00 to $35.00. The current price Surgery Partners (SGRY) is trading at is $23.95, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch